BMO Capital Downgrades Regeneron Pharma (REGN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $753.12 -1.27%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 36
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 36
Join SI Premium – FREE
BMO Capital downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Market Perform, price target raised $1 to $143.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $138.60 yesterday.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $138.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fastenal (FAST) PT Raised to $51 at DA Davidson
- Huber Research double downgrades Netflix to underweight, sets $70 price target
- Anheuser-Busch InBev (ABI:BB) (BUD) PT Lowered to EUR76 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
